LZ Lifescience unveils 'disruptive' launch
![](/46/pdcnewsitem/03/83/22/lx%20lifescience.jpg)
By replacing traditional paper-based systems with MES, companies are able to deal with exceptions in real-time so that batch records and device history records can be reviewed in parallel with manufacturing rather than post production.
Manufacturing software specialist LZ Lifescience is set to launch its latest product to the global pharmaceutical industry in a bid to shake up the marketplace by offering manufacturers ‘affordable access’ to a Manufacturing Execution System (MES).
Shopfloor-Online is a well-established, web-based product that has already been installed with hundreds of customers in different sectors across the world and the creation of the Lifescience edition has extended its functionality to meet the demanding MES requirements of the life science sector.
Driven by market demand, its launch comes at a time when there is increased pressure on IT and infrastructure spend across the pharmaceutical and outsourcing industry, which has become a reported industry-issue over the last few years.
Designed specifically for pharmaceutical companies, the online production management system focuses on plant operations so materials flow smoothly to help companies achieve ‘Right First Time’ manufacturing and faster product release.
To bolster its global launch initiative, LZ Lifescience has secured the services of high-profile MES executive Christian Fortunel to run its operations in the US as vice president and increase the software’s global reach.
Tim Barber, chairman and board director at LZ Lifescience, said: “We are delighted to have Christian on board and his appointment comes at a very exciting time as we launch our new MES product to the world.
“We firmly believe current MES options on the market are price prohibitive for most tier-2 pharmaceutical, medical device, biotechnology and contract manufacturing organisations. Our aim with Shopfloor-Online is to therefore disrupt the sector by providing manufacturers of all sizes a genuinely affordable option to automate production management systems.
“Our software allows organisations to simultaneously manage scheduling, production execution, workflow, quality and inventory all in place to increase plant production efficiency, reduce the risk and meet current regulations.
“It significantly reduces the pricing barriers and complex nature of the traditional MES, without sacrificing functionality. By reducing errors, costs and waste, Shopfloor-Online will boost productivity by 25%. With this in mind, we are confident most clients will realise a return on investment in just a year,” added Tim.
With over 15 years’ experience in providing production management solutions to the life science industry, Christian has worked in the software sector in numerous executive positions.
New appointment Christian said: “I am very excited to join LZ Lifescience. With its Shopfloor-Online software product, I believe it offers, by far, the best value to the life science industry to establish electronic records that meet all regulatory requirements.
“There is a mindset change underway across the industry with regards to firms being open about adopting and deploying web-based solutions and online tools so the timing of our launch could not be better.
“By offering companies a modular approach to pick, choose and build functionality based on their process and facility requirements, we are providing clients a level of flexibility that is not currently available on the market.”
Supported by a strong engineering division, the well-established Shopfloor-Online is already used by hundreds of clients worldwide. This new version will assist life science companies with improved regulatory compliance, lower production costs, a centralised point of information, increased equipment efficiency and reduced waste and inventory.
By replacing traditional paper-based systems with MES, companies are able to deal with exceptions in real-time so that batch records and device history records can be reviewed in parallel with manufacturing rather than post production.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance